tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Lenz Therapeutics price target raised to $56 from $48 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Lenz Therapeutics (LENZ) to $56 from $48 and keeps a Buy rating on the shares after the FDA approved Vizz eye drops for the treatment of presbyopia in adults. Based on conversations with optometrists and ophthalmologists with prior experience prescribing AbbVie’s (ABBV) first-generation presbyopia eye drop Vuity, the firm believes physicians remain “optimistic and receptive” to Vizz, the analyst tells investors.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1